Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Revenue (2018 - 2025)

Exagen (XGN) has disclosed Revenue for 8 consecutive years, with $16.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 21.79% year-over-year to $16.6 million, compared with a TTM value of $66.6 million through Dec 2025, up 19.65%, and an annual FY2025 reading of $66.6 million, up 19.65% over the prior year.
  • Revenue was $16.6 million for Q4 2025 at Exagen, down from $17.2 million in the prior quarter.
  • Across five years, Revenue topped out at $17.2 million in Q3 2025 and bottomed at $7.6 million in Q2 2022.
  • Average Revenue over 5 years is $13.4 million, with a median of $13.5 million recorded in 2023.
  • The sharpest move saw Revenue tumbled 40.45% in 2022, then skyrocketed 85.87% in 2023.
  • Year by year, Revenue stood at $12.7 million in 2021, then increased by 1.17% to $12.8 million in 2022, then rose by 7.23% to $13.8 million in 2023, then dropped by 0.8% to $13.7 million in 2024, then rose by 21.79% to $16.6 million in 2025.
  • Business Quant data shows Revenue for XGN at $16.6 million in Q4 2025, $17.2 million in Q3 2025, and $17.2 million in Q2 2025.